查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726260

全球Semaglutide市场：市场规模、份额、趋势分析（按产品、用途、给药途径、分销管道和地区）、细分市场预测（2025-2035 年）

Semaglutide Market Size, Share & Trends Analysis Report By Product (Ozempic, Wegovy, Rybelsus), By Application (Type 2 Diabetes Mellitus, Obesity), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2035
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

Semaglutide市场成长与趋势

根据Grand View Research, Inc.的最新报告，预计到2035年全球Semaglutide市场规模将达到936亿美元，预测期内的复合年增长率为10.47%。

随着全球糖尿病和肥胖症的盛行率不断上升，Semaglutide产业正经历成长。糖尿病管理中对Glucagon-Like Peptide-1受体促效剂(GLP-1 RA) 的需求不断增加，使得Semaglutide成为重要的治疗选择。市场受到监管部门的核准、扩大的临床适应症以及支持采用先进的糖尿病和减肥药的医疗保健成本的增加的推动。

Semaglutide市场的主要驱动因素包括第 2 型糖尿病和肥胖症的负担日益加重，这推动了对有效治疗性介入的需求。这种治疗药物在降低心血管风险和帮助控制体重方面的有效性已使其用途扩展到糖尿病治疗之外。此外，优惠的报销政策和日益普及的自我注射疗法也促进了市场的成长。旨在改善药物输送机制的持续研究和开发活动正在进一步增强其商业性潜力。

由于对医疗保健基础设施的投资不断增加以及对糖尿病管理的认识不断提高，新兴经济体的市场可能会扩大。此外，Semaglutide已被证明具有减肥功效，并已在多个地区核准，这可能会进一步渗透到肥胖症治疗市场。製药公司正在积极开发新配方，包括口服药物和联合治疗，以提高患者的依从性并拓宽市场准入。

Semaglutide产业的特点是研发投入高、法律规范严格、智慧财产权保护有力。大型製药企业主导着该行业，利用广泛的分销网络和伙伴关係关係来扩大其市场占有率。竞争格局由正在进行的临床试验、产品生命週期管理策略以及透过配方改进和扩大适应症来实现产品差异化的努力所塑造。

Semaglutide受到多项专利保护，涵盖其配方、製造流程和治疗用途。Semaglutide的关键专利延长至2030年代，从而限制了学名药的竞争并确保了主要製造商的持续市场独占权。投资于口服或缓释性等替代製剂的公司正在寻求进一步的专利保护，以延长原始到期日后的商业性可用性。

最近的市场案例是Semaglutide在肥胖症治疗等新治疗领域核准，大大扩展了其商业性潜力。市场领导也正在建立策略联盟和收购来增强其分销能力。此外，临床试验结果证明其比现有疗法具有更优异的疗效，这正在加强市场采用并鼓励对下一代製剂的进一步投资。

受糖尿病和肥胖症盛行率不断上升、药物输送技术不断进步以及持续研发倡议的推动，Semaglutide产业有望持续成长。虽然专利保护确保了近期的市场独占权，但替代配方或联合治疗的出现可能会改变竞争动态。产业参与企业继续专注于扩大其适应症和地理覆盖范围，以适应不断变化的市场格局。

Semaglutide市场：概述

  • 根据产品类型，Ozempic 将在 2024 年以 59.62% 的收入份额占据市场主导地位，这得益于强大的临床疗效、广泛的监管核准以及在 2 型糖尿病中的广泛应用。
  • 根据应用，2 型糖尿病将占据市场主导地位，2024 年的收入份额将达到 71.16%。
  • 根据给药途径，肠外给药途径占据市场主导地位，到 2024 年将占 88.46% 的份额。
  • 从销售管道来看，零售药局将引领市场，到2024年将占55.09%的份额。
  • 市场的主要参与企业包括诺和诺德、礼来、Viking Therapeutics、Lexicon Pharmaceuticals、Biocon 和Astra Zeneca。Semaglutide专利到期后，随着生物相似药製造商进入市场，竞争预计会更加激烈。
  • 2025年3月，诺和诺德的3b期STRIDE试验显示，Ozempic（Semaglutide1.0毫克）使患有第2型糖尿病和周边动脉疾病的成年患者的步行距离提高了13%。研究结果已在ACC2025上发表并发表在《刺胳针》杂誌。诺和诺德已向 EMA 和 FDA 提交了标籤延期申请。

目录

第一章 分析方法与范围

第二章执行摘要

第三章Semaglutide市场：驱动因素、趋势与范围

  • 市场联动展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析：按阶段
    • 专利到期分析
    • 定价分析
    • 竞争格局：专利到期后的Semaglutide市场中新兴的生物相似药

第四章Semaglutide市场：按产品分類的业务分析

  • 各产品市场占有率（2024 年及 2035 年）
  • 产品仪表板
  • 市场规模预测及产品趋势分析（2018-2035）
  • 奥泽姆皮克
  • 韦戈维
  • 鲁贝尔苏斯
  • 其他的

第五章Semaglutide市场：按应用进行的业务分析

  • 按应用分類的市场占有率（2024 年和 2035 年）
  • 特定于应用程式的仪表板
  • 按应用分類的市场规模预测和趋势分析（2018-2035）
  • 2型糖尿病
  • 肥胖
  • 其他的

第六章Semaglutide市场：依给药途径进行的业务分析

  • 按管理途径分類的市场占有率（2024 年和 2035 年）
  • 管理路线仪表板
  • 按管理途径分類的市场规模预测和趋势分析（2018-2035）
  • 肠外
  • 口服

第七章Semaglutide市场：按分销管道进行的业务分析

  • 按分销管道分類的市场占有率（2024 年和 2035 年）
  • 分销通路仪表板
  • 按分销管道分類的市场规模预测和趋势分析（2018-2035）
  • 医院药房
  • 零售药局
  • 网路药局

第八章Semaglutide市场：按地区分類的业务分析

  • 各地区市场占有率（2024 年及 2035 年）
  • 区域仪表板
  • 各地区市场规模预测及趋势分析（2018-2035）
  • 北美洲
    • 按国家/地区（2018-2035 年）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 参与企业概况
  • 公司市场地位分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Novo Nordisk A/S
    • Eli Lilly
    • Viking Therapeutics
    • Lexicon Pharmaceuticals
    • Biocon
    • AstraZeneca
Product Code: GVR-4-68040-549-6

Semaglutide Market Growth & Trends:

The global semaglutide market size is anticipated to reach USD 93.60 billion by 2035, growing at a CAGR of 10.47% during the forecast period, according to a new report by Grand View Research, Inc. The semaglutide industry is experiencing growth, driven by the increasing prevalence of diabetes and obesity worldwide. The rising demand for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes management has positioned semaglutide as a key therapeutic option. The market is influenced by regulatory approvals, expansion in clinical indications, and growing healthcare expenditures that support the adoption of advanced diabetes and obesity treatments.

The primary drivers of the market for semaglutide include the increasing burden of type 2 diabetes and obesity, which have escalated the demand for effective therapeutic interventions. The drug's efficacy in reducing cardiovascular risks and aiding weight management has led to expanded usage beyond diabetes treatment. Additionally, favorable reimbursement policies and the growing adoption of self-administered injectable therapies contribute to market growth. Continuous research and development (R&D) activities aimed at improving drug delivery mechanisms further enhance its commercial potential.

The market presents opportunities for expansion in emerging economies due to rising healthcare infrastructure investments and increasing awareness of diabetes management. There is also potential for further market penetration in obesity treatment, as semaglutide has demonstrated efficacy in weight reduction, leading to regulatory approvals in multiple regions. Pharmaceutical companies are actively exploring novel formulations, including oral versions and combination therapies, to enhance patient compliance and broaden market reach.

The semaglutide industry is characterized by high R&D investment, stringent regulatory oversight, and strong intellectual property protection. Leading pharmaceutical firms dominate the landscape, leveraging extensive distribution networks and partnerships to expand their market presence. The competitive environment is shaped by ongoing clinical trials, product lifecycle management strategies, and efforts to differentiate products through formulation advancements and expanded indications.

Semaglutide is protected by multiple patents that cover its formulation, manufacturing process, and therapeutic applications. The primary patent for semaglutide extends into the 2030s, limiting generic competition and ensuring continued market exclusivity for key manufacturers. Companies investing in alternative formulations, such as oral and extended-release versions, seek additional patent protections to extend commercial viability beyond initial expiration dates.

Recent market instances include regulatory approvals for semaglutide in new therapeutic areas, such as obesity treatment, which has significantly expanded its commercial potential. Market leaders have also engaged in strategic collaborations and acquisitions to strengthen distribution capabilities. Additionally, clinical trial results demonstrating superior efficacy compared to existing therapies have reinforced market adoption and driven further investment in next-generation formulations.

The semaglutide industry is poised for sustained growth, supported by increasing diabetes and obesity prevalence, technological advancements in drug delivery, and ongoing R&D initiatives. While patent protections ensure near-term market exclusivity, competitive dynamics may shift as alternative formulations and combination therapies emerge. Industry participants continue to focus on expanding indications and geographic reach to capitalize on the evolving market landscape.

Semaglutide Market Report Highlights:

  • Based on product, Ozempic dominated the market with a revenue share of 59.62% in 2024, driven by strong clinical efficacy, broad regulatory approvals, and increasing adoption for type 2 diabetes.
  • Based on application, Type 2 Diabetes Mellitus dominated the market and accounted for a revenue share of 71.16% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
  • Based on route of administration, parenteral route of administration dominated the market and accounted for a share of 88.46% in 2024, driven by the widespread adoption of Ozempic and Wegovy, both available as injectable formulations.
  • Based on distribution channel, retail pharmacies led the market and accounted for a share of 55.09% in 2024, driven by increasing consumer demand for GLP-1 receptor agonists like Ozempic and Wegovy.
  • Key market players include Novo Nordisk, Eli Lilly, Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, and AstraZeneca. Competition is expected to intensify as biosimilar manufacturers enter the market after semaglutide's patent expires.
  • In March 2025, Novo Nordisk's phase 3b STRIDE trial showed that Ozempic (semaglutide 1.0 mg) improved walking distance by 13% in adults with type 2 diabetes and PAD. Results were presented at ACC 2025 and published in The Lancet. Novo Nordisk has submitted a label extension application to the EMA and FDA.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Semaglutide Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis, by Phase
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis
    • 3.3.6. Competitive Landscape: Emerging Biosimilars in the Post-Patent Semaglutide Market

Chapter 4. Semaglutide Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2035
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2035 (USD Million)
  • 4.4. Ozempic
    • 4.4.1. Ozempic Market, 2018 - 2035 (USD Million)
  • 4.5. Wegovy
    • 4.5.1. Wegovy Market, 2018 - 2035 (USD Million)
  • 4.6. Rybelsus
    • 4.6.1. Rybelsus Market, 2018 - 2035 (USD Million)
  • 4.7. Others
    • 4.7.1. Other Product Market, 2018 - 2035 (USD Million)

Chapter 5. Semaglutide Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2035
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2035 (USD Million)
  • 5.4. Type 2 Diabetes Mellitus
    • 5.4.1. Type 2 Diabetes Mellitus Market, 2018 - 2035 (USD Million)
  • 5.5. Obesity
    • 5.5.1. Obesity Market, 2018 - 2035 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2035 (USD Million)

Chapter 6. Semaglutide Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2035
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2035 (USD Million)
  • 6.4. Parenteral
    • 6.4.1. Parenteral Market, 2018 - 2035 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral Market, 2018 - 2035 (USD Million)

Chapter 7. Semaglutide Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2035
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2035 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2035 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2035 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2018 - 2035 (USD Million)

Chapter 8. Semaglutide Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2035
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2035:
  • 8.4. North America
    • 8.4.1. North America Semaglutide Market Estimates And Forecasts, By Country, 2018 - 2035 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novo Nordisk A/S
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Eli Lilly
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Viking Therapeutics
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Lexicon Pharmaceuticals
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Biocon
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. AstraZeneca
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global semaglutide market, by region, 2018 - 2035 (USD Million)
  • Table 4. Global semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 5. Global semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 6. Global semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 7. Global semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 8. North America semaglutide market, by country, 2018 - 2035 (USD Million)
  • Table 9. North America semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 10. North America semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 11. North America semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 12. North America semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 13. U.S. semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 14. U.S. Semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 15. U.S. semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 16. U.S. semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 17. Canada semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 18. Canada semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 19. Canada semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 20. Canada semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 21. Mexico semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 22. Mexico semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 23. Mexico semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 24. Mexico semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 25. Europe semaglutide market, by country, 2018 - 2035 (USD Million)
  • Table 26. Europe semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 27. Europe semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 28. Europe semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 29. Europe semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 30. UK semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 31. UK Semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 32. UK semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 33. UK semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 34. Germany semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 35. Germany semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 36. Germany semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 37. Germany semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 38. France semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 39. France Semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 40. France semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 41. France semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 42. Italy semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 43. Italy semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 44. Italy semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 45. Italy semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 46. Spain semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 47. Spain semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 48. Spain semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 49. Spain semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 50. Norway semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 51. Norway Semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 52. Norway semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 53. Norway semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 54. Denmark semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 55. Denmark semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 56. Denmark semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 57. Denmark semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 58. Sweden semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 59. Sweden semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 60. Sweden semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 61. Sweden semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 62. Asia Pacific semaglutide market, by country, 2018 - 2035 (USD Million)
  • Table 63. Asia Pacific semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 64. Asia Pacific semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 65. Asia Pacific semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 66. Asia Pacific semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 67. Japan semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 68. Japan semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 69. Japan semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 70. Japan semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 71. China semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 72. China semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 73. China semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 74. China semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 75. India semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 76. India semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 77. India semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 78. India semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 79. Australia semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 80. Australia semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 81. Australia semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 82. Australia semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 83. South Korea semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 84. South Korea semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 85. South Korea semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 86. South Korea semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 87. Thailand semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 88. Thailand semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 89. Thailand semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 90. Thailand semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 91. Latin America semaglutide market, by country, 2018 - 2035 (USD Million)
  • Table 92. Latin America semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 93. Latin America semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 94. Latin America semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 95. Latin America semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 96. Brazil semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 97. Brazil semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 98. Brazil semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 99. Brazil semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 100. Argentina semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 101. Argentina semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 102. Argentina semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 103. Argentina semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 104. Middle East & Africa Semaglutide market, by country, 2018 - 2035 (USD Million)
  • Table 105. Middle East & Africa semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 106. Middle East & Africa semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 107. Middle East & Africa semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 108. Middle East & Africa semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 109. South Africa semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 110. South Africa semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 111. South Africa semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 112. South Africa semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 113. Saudi Arabia semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 114. Saudi Arabia semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 115. Saudi Arabia semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 116. Saudi Arabia semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 117. UAE semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 118. UAE semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 119. UAE semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 120. UAE semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 121. Kuwait semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 122. Kuwait semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 123. Kuwait semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 124. Kuwait semaglutide market, by distribution channel, 2018 - 2035 (USD Million)

List of Figures

  • Fig. 1 Semaglutide market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Semaglutide market dynamics
  • Fig. 12 Semaglutide market: Porter's five forces analysis
  • Fig. 13 Semaglutide market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2035 (USD Million)
  • Fig. 15 Ozempic market, 2018 - 2035 (USD Million)
  • Fig. 16 Wegovy market, 2018 - 2035 (USD Million)
  • Fig. 17 Rybelsus market, 2018 - 2035 (USD Million)
  • Fig. 18 Others market, 2018 - 2035 (USD Million)
  • Fig. 19 Application market, 2018 - 2035 (USD Million)
  • Fig. 20 Type 2 Diabetes Mellitus market, 2018 - 2035 (USD Million)
  • Fig. 21 Obesity market, 2018 - 2035 (USD Million)
  • Fig. 22 Others market, 2018 - 2035 (USD Million)
  • Fig. 23 Route of Administration market, 2018 - 2035 (USD Million)
  • Fig. 24 Parenteral market, 2018 - 2035 (USD Million)
  • Fig. 25 Oral market, 2018 - 2035 (USD Million)
  • Fig. 26 Distribution Channel market, 2018 - 2035 (USD Million)
  • Fig. 27 Hospital Pharmacies market, 2018 - 2035 (USD Million)
  • Fig. 28 Retail Pharmacies market, 2018 - 2035 (USD Million)
  • Fig. 29 Online Pharmacies market, 2018 - 2035 (USD Million)
  • Fig. 30 Semaglutide market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 40 Europe semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 45 France country dynamics
  • Fig. 46 France semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 57 Asia Pacific semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 60 China country dynamics
  • Fig. 61 China semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 62 India country dynamics
  • Fig. 63 India semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 70 Latin America semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 75 MEA semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework